Alleh Lindquist is the CEO of Floraworks, a company focused on cannabinoid therapeutics for health and wellness. With a background in chemistry, Alleh and her team have been working on developing a pathway to produce CBN at scale. They are dedicated to unlocking the therapeutic potential of cannabinoids and understanding how they interact with the human body.

Alleh Lindquist, the CEO of Floraworks, discusses the company's focus on cannabinoid therapeutics for health and wellness. They have been working on developing a pathway to produce CBN at scale and have conducted studies to validate its efficacy as a natural sleep aid. The results showed that 50 milligrams of CBN had a significant effect on improving sleep compared to a placebo and even outperformed melatonin. Flora Works sees CBN as a disruptor in the market, offering a new option for those who have not found relief from existing sleep aids.